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Abstract:MicroRNAs (miRNAs) are small single-stranded, non-coding RNAmolecules involved in the pathogenesis and
progression of cancer, including osteosarcoma. We aimed to clarify the pathways involving miRNAs using new
bioinformatics tools. We applied WikiPathways and PathVisio, two open-source platforms, to analyze miRNAs in
osteosarcoma using miRTar and ONCO.IO as integration tools. We found 1298 records of osteosarcoma papers
associated with the word “miRNA”. In osteosarcoma patients with good response to chemotherapy, miR-92a, miR-
99b, miR-193a-5p, and miR-422a expression is increased, while miR-132 is decreased. All identified miRNAs seem to
be centered on the TP53 network. This is the first application of PathVisio to determine miRNA pathways in
osteosarcoma. MiRNAs have the potential to become a useful diagnostic and prognostic tool in the management of
osteosarcoma. PathVisio is a full pathway editor with the potentiality to illustrate the biological events, augment
graphical elements, and elucidate all the physical structures and interactions with standard external database identifiers.
Introduction
Osteosarcoma (OS) is the most common primary malignant
bone tumor, comprising about 20% of primary bone
sarcomas. It is a high-grade malignant tumor characterized
by the cells forming immature bone or osteoid. The tumor
is considered primary when the underlying bone is normal
and secondary when it is altered by a pre-existing condition
such as prior irradiation or Paget disease (Osasan et al.,
2016; Sergi and Zwerschke, 2008). OS is slightly more
prevalent in males (male:female = 3:2) and has a bimodal
age distribution with a preference for the adolescent and
geriatric age groups, with most of the primary OS cases (60–
70%) affecting adolescents and young adults (from 15 to 25
years of age). In the elderly, OS is usually associated with
Paget disease of the bone, post-radiation sarcoma, and
dedifferentiated chondrosarcomas (Sergi and Zwerschke,
2008). Primary OS may arise in any bone, generally in the
long bones of the appendicular skeleton (80–90%), most
commonly in the distal femur, proximal tibia, and proximal
humerus. Within the long bones, the tumor is usually
located in the metaphysis and arises as an enlarging and
palpable mass, which results in progressive pain. OS
originating in the mid-shaft of bones is uncommon.
Conversely, tumors arise e often in the epiphysis where the
growth plate is located. Less than 1% of OS is found in the
bones of the hands and feet. There is an increase in
osteosarcoma’s relative incidence in non-long bones,
including the jaws, pelvis, spine, and skull within the senior
age group. The standard first-line treatment regimens for
OS include surgery and multi-agent chemotherapy. Almost
all patients receive a neoadjuvant intravenous combination
of doxorubicin and cisplatin with or without methotrexate
as the initial chemotherapy regimen. In cases where surgical
resection is not feasible or the margins are inadequate, the
use of radiation therapy may improve local control, but this
is not considered a standard of care in pediatric and young
adult patients. There has been a significant increase in the
5-year survival rates of patients with OS due to the advances
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in patients’ clinical management. Most centers’ survival rates
now exceed 50%, but patients presenting with metastatic and
recurrent disease have a survival rate of below 20%. The lung
is the leading site of metastatic deposits (Abarrategi et al.,
2016; Chen et al., 2016b).
Osteosarcoma and genetics
Some genetic syndromes are associated with an increased risk
of OS. They include hereditary retinoblastoma (germline
mutation of the Rb gene), Li-Fraumeni syndrome (germline
mutation of the TP53 gene), Bloom syndrome (germline
mutation of the RECQL2 gene), Werner syndrome
(germline mutation of the RECQL3 gene), and Rothmund-
Thomson syndrome (germline mutation of the RECQL4
gene) (Osasan et al., 2016). The two most prominent genes
that harbor germline mutations in patients with OS are the
retinoblastoma (Rb 1) and the TP53 tumor suppressor
genes. Most OS demonstrate inactivation of both the
retinoblastoma (Rb) and p53 pathways. OS has a
disorganized genome characterized by complex, unbalanced
karyotypes with varying patterns of abnormalities. The most
consistent finding beyond the TP53 and RB genes’
dysregulation is significant aneuploidy with some evidence
of chromothripsis. Chromothripsis is the phenomenon by
which up to hundreds to thousands of clustered
chromosomal rearrangements occur in a single event in
localized and confined genomic regions in one or a few
chromosomes (Ly and Cleveland, 2017; Poot, 2017; Smida
et al., 2017). These findings suggest an early defect in DNA
repair/surveillance as a mechanism for the pathogenesis of
OS (Behjati et al., 2017). Tumor suppressor genes function
to control cell growth by inhibiting cell proliferation and
tumor development. Also, they play a role in cell repair and
apoptosis. When tumor suppressors mutate, resulting in a
loss or reduction in function, there is an increase in the
likelihood of developing cancer. The retinoblastoma (RB)
was the first tumor suppressor gene described and encodes a
protein that functions as a negative regulator of the cell
cycle (Ren and Gu, 2017). This protein stabilizes
constitutive heterochromatin to maintain overall chromatin
structure. RB1 is the checkpoint that binds the E2F family
of transcription factors and inhibits cell cycle progression.
Defects in this gene are associated with retinoblastoma,
urinary bladder cancers, and OS. The RB gene is critical for
the regulation of the G1 to S cell cycle transition. In the
absence of mitogenic stimuli, Rb remains dephosphorylated
and binds to E2F family transcription factors, preventing
their activation of the cell cycle. Mutations that result in the
loss of function of the RB protein occur in approximately
70% of OS, mostly due to a loss of heterozygosity. Structural
rearrangements and point mutations in the RB gene can
also occur (Ren and Gu, 2017). The TP53 gene functions as
a tumor suppressor in essentially all tumors. It encodes a
tumor suppressor protein, which contains transcriptional
activation, DNA binding, and oligomerization domains.
This protein plays a crucial role in maintaining genomic
stability functioning as a transcription factor that regulates
the expression of various genes involved in cell cycle arrest,
DNA repair, changes in metabolism, and apoptosis.
Mutations in this gene are associated with a wide variety of
cancers, including OS. The function of p53 can be affected
by mutations in the gene itself or by mutations to up- or
downstream mediators of its activity. Mutations that result
in the loss of function of the p53 gene occur in
approximately 75% of OS cases. The mutations in the TP53
gene include allelic loss (75–80%), rearrangements (10–
20%), and point mutations (20–30%) (Braithwaite et al.,
2017; Duffy et al., 2017; Gold, 2017; Guha and Malkin,
2017; Kastenhuber and Lowe, 2017; Merkel et al., 2017). In
the RB pathway setting, E2F3 and CDK4, both of which
counteract RB control of cell cycle progression, are
estimated to possess gain of function mutations. E2F3 is
found in 60% of tumors, while CDK4 is found in 10% of
tumors (Sampson et al., 2015). Within the p53 pathway,
MDM2 is an E3 ubiquitin ligase that acts as a negative
regulator of p53. The MDM2 gene is amplified in 3–25% of
OS. COPS3 promotes the proteasomal degradation of p53,
and COPS3 amplification is seen in 20–80% of OS cases. In
the c-Myc pathway, the c-Myc gene is a key transcription
factor that functions as a general amplifier of gene
expression (Iaccarino, 2017). It enhances the transcription
of essentially all genes with active promoters within the cell.
This gene is amplified in 7–67% of OS cases and over-
expressed in at least 30% of tumors (Morrow and Khanna,
2015; Sampson et al., 2015).
Role of MiRNA in osteosarcoma
MicroRNAs (miRNAs) are a small single-stranded, non-
coding RNA molecule (from 18 to 25 nucleotides in length),
which are usually found in eukaryotic cells. They are
involved in various biological processes that regulate
differentiation, apoptosis, and proliferation of numerous
non-neoplastic and neoplastic diseases (Dong et al., 2016;
Hashimoto and Tanaka, 2017; Leichter et al., 2017; Nugent,
2014; Ram Kumar et al., 2016; Sampson et al., 2015; Sergi
et al., 2017a; Sergi et al., 2017b; Zhao et al., 2013). This
process is achieved by complementarily pairing with the 3’
untranslated region (3’ UTR) or 5’ untranslated region (5’
UTR) of target genes, thus inhibiting the mRNA translation
of these genes. In 1993, miRNA was first discovered in the
nematode species C. elegans, and the first molecule was
named lin-4. Since this discovery, it has been estimated that
as many as 1000 miRNAs exist in the human genome, with
more than 30% of the human genome regulated by miRNAs
that simultaneously target multiple genes. In the last decade,
it became clear that miRNAs are implicated in the
pathogenesis of cancer, including OS (Ram Kumar et al.,
2016). This aspect was demonstrated by the differences in
the miRNA expression profiles detected between normal
and cancer cells. The expression of many different types of
miRNA was found to be altered (either over-expressed or
reduced) in malignancy. MiRNAs can function as tumor
suppressors, oncogenes, or both. The dysregulation of
miRNA expression may contribute to cancer development
through the loss of controls of biological processes. These
natural and physical properties can make miRNAs useful
diagnostic and prognostic tools in the management of
various cancers, including OS and non-oncological diseases
(Agarwal et al., 2015; Chen et al., 2016a; Chen et al., 2013;
Dong et al., 2016; Hsu et al., 2011; Jones et al., 2012;
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Kobayashi et al., 2012; Leichter et al., 2017; Lin et al., 2016;
Nugent, 2014; Ram Kumar et al., 2016; Sampson et al.,
2015; Zhao et al., 2013; Zhou et al., 2016). There is
increasing evidence that multiple miRNAs may play a
role in determining the response to chemotherapy in the
treatment of OS (Ram Kumar et al., 2016; Sampson
et al., 2015).
Bioinformatics
In the last two decades, numerous bioinformatics tools have
been developed to manage the increasing abundance of data.
The massive flow of miRNA data can be handled effectively
and efficiently using specific bioinformatics tools. In
targeting miRNAs, we can address the identification,
expression, and analysis of explicit and multiple miRNAs,
establish miRNA regulatory networks, miRNA metabolic
and signaling pathways, and miRNA-transcription factor
interplay, thereby linking miRNAs to particular diseases or
status of the disease. WikiPathways is an open, collaborative
platform for drawing, editing, and sharing biological
pathways, built using the same software underlying
Wikipedia. This platform can be used to integrate, visualize,
and analyze system-wide transcriptomics, proteomics, and
metabolomics data. Several studies have demonstrated
miRNAs’ involvement in the pathogenesis, diagnostic
potential, and therapeutics of OS. As indicated above, these
miRNAs have been re-emphasized most recently because
they intrinsically regulate the expression of different genes
that play essential roles in tumorigenesis, cell invasion,
migration, and metastasis. In this review, we aimed to
discuss the current knowledge of miRNAs’ role and their
target genes in OS and attempt to develop an OS pathway
involving miRNA integrating WikiPathways and other
bioinformatic tools.
Materials and Methods
PubMed, Scopus, and Google Scholar were used to
systematically search for reviewed publications that
investigated the functions of miRNA in the pathogenesis,
treatment, and prognosis of osteosarcoma. Publications in
the time frame “2008-2018” and targeting “miRNA” and
“Osteosarcoma” were retrieved from the archives. The
findings from these publications were used to compile a list
of miRNAs that are associated with OS. This study relies on
a systematic search, but it does not comply with PRISMA
eligibility criteria (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses).
PathVisio, a no-cost open-source pathway editor,
visualization, and analysis software, has significantly
enhanced the capacity to explore large scale data. It provides
an invaluable tool for investigating genes, proteins, and
metabolites in both the healthy and diseased states of
complex tissues and related diseases, including OS. We used
PathVisio as a pathway editor, visualization, and analysis
software. Since the first publication of PathVisio in 2008, the
software has been cited more than 170 times and used in
many different biological studies. As an online editor,
PathVisio is also integrated into the community curated
pathway database WikiPathways. Wikipathways is one of
the most popular freely available databases for assessing
biological pathways. It is an open, collaborative platform
used to create and share paths and is known as a plugin for
PathVisio. PathVisio 3 is a free open-source pathway editor,
visualization, and analysis toolbox implemented in Java, a
class-based, object-oriented programming language able to
run on all major operating systems (Bhat et al., 2018;
Kutmon et al., 2015). The miRTar bioanalysis tool was used
to determine miRNAs’ interaction with genes in the TP53
pathway (Hsu et al., 2011). In particular, the miRTar tool
adopts seven scenarios to identify putative miRNA target
sites of the gene transcripts. It illustrates the biological
functions of miRNAs concerning their targets in metabolic
pathways. The prediction system helps biologists to quickly
identify the regulatory relationships between crucial
miRNAs and their targets.
The results were used in assembling the pathway for OS.
Common miRNAs that have been previously identified in
studies to have a role in the development and progression of
OS were selected from the literature and imputed into this
tool to identify the targeted genes. A pathway network was
constructed using the ONCO.IO micro-analysis tool. A
pathway for miRNAs linked to OS was then built using
PathVisio and the Wikipathways plugin. The URLs of the




There is a significant number of miRNAs that we found to be
associated with OS. We found 1298 records of osteosarcoma
papers associated with the word “miRNA”. Three studies
were substantially selected from which miRNAs associated
with osteosarcoma were used for further detailed analysis
(Chen et al., 2016a; Kobayashi et al., 2012; Nugent, 2014).
In these studies,
A total of 6 miRNAs were found on chromosome 1,
making chromosome 1 the most popular miRNA location.
Chromosomes X and 11 were the second most frequent
miRNA locations, with each chromosome being responsible
for five miRNAs. The third most common chromosomal
location for miRNAs is chromosome 19, responsible for
four miRNAs. In addition, miRNAs are also located on
chromosomes 3, 4, 5, 6, 7, 9, 13, 14, 15, 16, 17, 18, 20, and
21. All types of cellular pathways from development to
oncogenesis are affected by miRNAs. Tab. 1 highlights the
miRNAs associated with OS. Tabs. 2 and 3 recapitulate the
roles and target genes of miRNAs in OS, with Tab. 2
displaying those with increased expressions and Tab. 3
displaying those with decreased expressions. A careful
perusal of the literature showed that OS has increased
expression of miR-21, miR-93, miR-135b, miR-150, miR-
210, miR-221, miR-199b-5p, miR-218, miR-542-5p, and
miR-652. While target genes are known for each of these
miRNAs, the role in which they play is only known for
miR-21, miR-93, miR-221, and miR-199b-5p. Conversely,
there was decreased expression of miR-16, miR-24,
miR-29a, miR-29b, miR-31, miR-34a, miR-34b, miR-34c,
miR-125b, miR-132, miR-133a, miR-143, miR145, miR-183,
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TABLE 1
Experimental groups highlighting the MiRNAs associated with osteosarcoma (Kutmon et al., 2015)
miRNA Expression Chromosome Start End
miR-16-1 Decreased 13 49521110 46521198
miR-16-2 Decreased 3 1.62E+08 1.62E+08
miR-21 Increased 17 55273409 55273480
miR-24-1 Decreased 9 6888124 6888191
miR-24-2 Decreased 19 13808101 13808173
miR-29a Decreased 7 1.3E+08 1.3E+08
miR-29b-1 Decreased 7 1.3E+08 1.3E+08
miR-29b-2 Decreased 1 2.06E+08 2.06E+08
miR-31 Decreased 9 21502114 21502184
miR-34a Decreased 1 9134314 9134423
miR-34b Decreased 11 1.11E+08 11088956
miR-34c Decreased 11 1.11E+08 1.11E+08
miR-92a-1 Increased 13 90801569 90801646
miR-92a-2 Increased X 1.33E+08 1.33E+08
miR-93 Increased 7 99529327 99529406
miR-99b Increased 19 56887677 56887746
miR-125b-1 Decreased 11 1.21E+08 1.21E+08
miR-125b-2 Decreased 21 16884428 16884516
miR-132 Decreased 17 1899952 1900052
miR-133a-1 Decreased 18 17659657 17659744
miR-133a-2 Decreased 20 60572564 60572665
miR-135b Increased 1 2.04E+08 2.04E+08
miR-136 14 1E+08 1E+08
miR-140 Increased 16 68524485 68524584
miR-143 Decreased 5 1.49E+08 1.49E+08
miR-145 Decreased 5 1.49E+08 1.49E+08
miR-150 Increased 19 54695854 54695937
miR-183 Decreased 7 1.29E+08 1.29E+08
miR-192 11 64415185 64415294
miR-199a-3p Decreased 19 10789102 10789172
miR-199b-5p Increased 9 1.3E+08 1.3E+08
miR-200a Decreased 1 1093106 1093195
miR-200b Decreased 1 1092347 1092441
miR-200c Decreased 12 6943123 6943190
miR-206 Decreased 6 52117106 52117191
miR-210 Increased 11 558089 558198
miR-215 1 2.18E+08 2.18E+08
miR-218-1 Increased 4 20138996 20139105
miR-218-2 Increased 5 1.68E+08 1.68E+08
miR-221 Increased X 45490529 45490638
miR-335 Decreased 7 1.3E+08 1.3E+08
miR-340 Decreased 5 1.79E+08 1.79E+08
miR-422a Increased 15 61950182 61950271
miR-424 Decreased X 1.34E+08 1.34E+08
miR-542-5p Increased X 1.34E+08 1.34E+08
miR-652 Increased X 1.09E+08 1.09E+08
20 MERVIN BURNETT et al.
TABLE 2
MiRNAs with increased expression in osteosarcoma (Hsu et al., 2011; Nugent, 2014)
miRNA Role Target gene
miR-21 Cell invasion and migration via regulation of RECK SERPINB5, THBS1
miR-93 Increased cell proliferation and invasion ATM, CASP8, CCND2, CD82, CYCS, SERPINE1, TP53, ZMAT3
miR-135b CCND2, PPM1D
miR-150 CCND1, RPRM, TP53
miR-210 ATR, IGFBP3
miR-221 Induces cell survival via inhibition of PTEN CCND2, CYCS,
miR-199b-5p Involved in Notch signaling BBC3, CDKN1A, IGFBP3, SESN1,TP53
miR-218 CYCS, CCND2
miR-542-5p CCND3, CDKN2A, SHISA5, TP73
miR-652 CASP3, CYCS
TABLE 3
MiRNAs with decreased expression in osteosarcoma
miRNA Role Target gene
miR-16 Inhibition of cell proliferation via IGFIR CCND2, CDK6, CDKN2A, CHEK1, PPM1D, SESN2, SIAH1
Inhibition of osteosarcoma cell proliferation via LPAATβ
downregulation
miR-24 BBC3, CASP8, CASP3, CCND2, CDK2, CDKN2A, CCYS, PPM1D,
SESN1, TNFRSF10B
miR-29a Induces apoptosis CASP8, CASP9, CDKN2A, CYCS, IGF1, PPM1D, TNFRSF10B
miR-29b Osteogenic differentiation of mesenchymal stem cells via
regulation of bone
CCND3
miR-31 transcription factor Osterix
miR-34a Inhibition of cell proliferation via Notch- 1 inhibition BID, CASP9, CCNE2, CDK6, E124, IGF1, LRDD, SERPINE1,
THBS1
miR-34b Suppresses proliferation of osteoclasts GTSE1
miR-34c by downregulation of Runx2
miR-125b Suppresses Proliferation via down- regulation of STAT3
miR-132 Facilitates angiogenesis
miR-133a Promotes apoptosis by targeting Bcl-xL
and Mcl-l
CCND2, SHISA5, TNFRSF10B
miR-143 Inhibition of cell proliferation
miR-145 via Notch- 1 inhibition




miR-200 Inhibition of cell proliferation via Notch- 1 inhibition
miR-206 Involved in apoptosis and inhibition
cell invasion and migration
CCND2, IGF1
miR-335 Suppresses migration and invasion by targeting ROCK1
miR-340 Suppresses proliferation, migration, and invasion by
targeting ROCK1
miR-424 Inhibits migration and invasion via fatty
acid synthase
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miR-199a-3p, miR-200, miR-206, miR-335, miR-340 and
miR-424. Roles are defined for all the miRNAs except miR-
29b, miR-34b, and miR143. Target genes have been
identified for miR-16, miR-29a, miR-29b, miR-31, miR-34a,
miR-34b, miR-133a and miR-206. The interconnection of
these miRNAs with signaling pathways was the next step in
our analysis and the miRNAs with OS intrinsic regulation
are key and displayed in Tab. 4.
Fig. 1 shows the TP53 Network built by ONCO.IO, a
bioinformatic tool on PathVisio software, and the miRNA-
regulation of TP53 in OS, respectively. The weight of miR34
for transcriptional regulation is prominent.
The purpose of this study was to attempt to construct a
pathway involving the miRNA regulation of the p53
signaling pathway for OS. No unique, perpetual, and solid
pathway involving miRNAs for OS was found, but there are
multiple pathways related to the TP53 gene which are
associated with different conditions. Data regarding miRNA
and target genes involved in the development and
progression of OS corresponded to information that was
published in previous studies. This data was imputed into
onco.io to generate a signaling pathway for p53 that shows
miRNA regulation. Fig. 1 is exclusively an example of
multiple genetic interactions that can be revealed using
PathVisio. It does not mean that it is comprehensive of all
genes-miRNAs interaction as networks. The gray shadow of
the left corner of Fig. 1 is supposed to polarize the attention
on some molecules of interest, but it can be displayed in
other locations according to different research questions.
Discussion
The mechanism of action of miRNAs in OS remains not
clearly understood. However, the TP53 gene is mutated in
more than 20% of OS, with mutations demonstrated to be
involved in tumorigenesis. MiRNAs are involved in the
control of many cellular processes, and the dysregulation of
miRNA expression can influence carcinogenesis once tumor
suppressor genes or oncogenes encode the relevant target
mRNAs. Even a small variation can have significant
implications for the cell since each miRNA can have many
targets. In humans, it has been established that many
miRNA genes are located in cancer-associated regions or at
the fragile sites of chromosomes, which are prone to
deletion, amplification, and mutations in cancer cells. Since
miRNAs can function as negative regulators of gene
expression, an over-expression of oncogenic miRNAs can
contribute to tumor development by promoting cellular
proliferation and evasion of apoptosis. A similar effect will
occur if there is a reduction in the expression of tumor-
suppressive miRNAs. Research has demonstrated both
increases and decreases in the expression of specific
miRNAs in cancer. These appear to vary depending on the
particular tissue and the cancer type (He et al., 2007; Kao
et al., 2012; Kobayashi et al., 2012). Several miRNAs have
been identified as direct targets of p53.
The miR-34 family (miR-34a, miR-34b, and miR-34c)
has been an important component of the p53 tumor
suppressor pathway. P53 induces the expression of these
miRNAs in response to DNA damage and oncogenic stress
in many cancers. He et al. (2007) reported that the miR-34
family induces G1 arrest and apoptosis via their targets
CDK6, E2F3, Cyclin E2, and BCL2 in a p53-dependent
manner in OS cells (Bhat et al., 2018). The expression of
miR-34 is decreased in OS, and miR-34 enhances p53
mediated cell cycle arrest and apoptosis. Also, p53 induces
the upregulation of miR-192, miR-194, and miR215 in
U2OS cells, which carry the wild-type p53. The loss of
TABLE 4
MiRNAs with intrinsic regulation in osteosarcoma
miRNA Function in OS Expression MiRNA target in OS
miR-34a, P53 related G1 arrest and apoptosis Decreased CDK6, E2F3,
miR-34b, Cyclin E2, BCL2
miR-34c
miR-31 Cell proliferation Increased E2F3
miR-192, P53 related cell cycle arrest Increased CDKN1A/p21
miR-215
miR-140 Chemoresistance to MTX and 5- FU Increased HDAC4
miR-215 Chemoresistance to MTX Increased DTL





miR-21 Cell invasion and migration Increased RECK, MET, mTOR, STAT3, MCL-1
miR-199a-3p Cell proliferation and migration Decreased BCL-X
miR-143 Pulmonary metastasis Increased MMP-13
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miR-31 is associated with defects in the p53 pathway, while
overexpression of miR-31 significantly inhibits OS cells’
proliferation. Moreover, miR-31 seems to have the potential
to prevent disease progression or the development of
pulmonary metastasis in OS (Kao et al., 2012; Kobayashi
et al., 2012).
Biological pathways are descriptive. Sometimes complex
diagrams are used to summarize and describe physical
processes. These pathways show the potential interaction
among genes, proteins, and metabolites. Path diagrams are a
common way to graph the wealth of information available
on these biological processes. To the best of our knowledge,
no established pathways involving miRNAs for OS has been
confirmed so far. However, there are multiple pathways
related to TP53, which are associated with different disease
conditions. The purpose of this study was to construct a
path involving the miRNA regulation of the p53 signaling
pathway for OS using PathVisio. Data regarding miRNA
and target genes involved in the development and
progression of OS corresponds to information that is
available in the biomedical research literature. There is
significant involvement of miRNAs in the development,
progression, and metastasis of OS. The involvement spans
from gene expression to epigenetics.
MiRNAs and their identified target genes are associated
with multiple biological pathways and functions related to
bone biology and cancer development and progression.
Dysregulation of miRNAs is thereby associated with
tumorigenesis in OS. A study by Andersen et al. (2018)
investigated the miRNA expression in 101 OS samples
(Andersen et al., 2018). A total of 752 miRNAs were
profiled, with 33 of these being identified as deregulated in
OS. Andersen et al. (2018) found a significant role of
miRNAs in the tumorigenesis of OS and that 29 deregulated
miRNAs were strongly correlated with cancer development
and progression. MiR-221 and miR-222 are associated
significantly with time to metastasis. Significant
downregulated miRNAs were identified as miR-100-5p,
miR-125b-5p, miR-127-3p, miR-370-3p, miR-335-5p and
miR-411-5p. Scott et al. (2007) and Sempere et al. (2004)
showed that miR-125b is an important regulator of both
proliferation and differentiation of different cell types. At
the same time, Mizuno et al. (2008) indicated that miR-
125b inhibits normal OB proliferation in mouse cells and
plays a role in bone development and OS tumorigenesis.
Andersen et al. (2018) also identified miR-181a-5p, miR-
181c-5p, miR-223-3p and miR-342-3p as being significantly
upregulated in OS.
Our study was done to summarise and further increase
our understanding of the roles played by various miRNAs at
various stages of the signaling pathway regulated by TP53 in
OS. Improved knowledge would allow for the development
of specific miRNAs as biomarkers for diagnosis, disease
monitoring, and OS progression. The possibility exists that
miRNAs may have a therapeutic role in managing OS in the
nearest future, particularly with the adoption of protocols of
personalized medicine, renewed gene technologies, and
digital pathology (Burnett et al., 2020; Jin et al., 2020; Sergi,
2019). MiRNA-directed gene regulation will pave the way
for improving traditional gene therapy approaches to
cancer, including OS. Presently, validation of miRNA
pathways and targets in metastatic osteosarcoma has not
been determined. Still, miRNA plays a role in the
progression of OS by regulating proliferation, invasion,
adhesion, metastasis, apoptosis, and angiogenesis.
Identifying dysregulated miRNAs in patients with OS may
contribute to the development of biomarkers for diagnosis
and prognosis. There are challenges faced in identifying all
the targets of miRNAs and establishing their contribution
towards malignancy. Circulating miRNAs are considered
predictive biomarkers for various types of cancers. They can
be used as non-invasive disease biomarkers in cancer since
they exist in human serum and plasma in remarkably stable
forms. Comprehensive screening of miRNA profiles would
allow for earlier detection of OS, as well as nullify the need
for the collection of tissue samples through invasive
procedures such as biopsies. Despite the clinical potential
for the use of miRNAs as diagnostic biomarkers, several
limitations are present. In most studies, the cohort of
patients used has been relatively small, and therefore
evaluations of large, long-term sample sizes with long-term
follow-up are required. There is a lack of standardized
approaches in the methodology of the normalization of
circulating miRNAs. A refined approach is needed in future
FIGURE 1. TP53 results are intimately linked to MiR34A, MiR34B,
MiR125B1, MiR125B2, MiR145, MiR150, and MiR215.
Some genes, which are intrinsically modulating TP53 gene
expression, are depicted (CASP8, CHEK1, FAS, MDM2, SESN1).
The CASP8 gene is responsible for the production of a member of
the cysteine-aspartic acid protease family. The sequential activation
of caspases is critical in the execution-phase of the programmed
cell death or apoptosis. CHEK1 is the gene for the serine/
threonine-specific protein kinase, which coordinates the DNA
damage response and cell cycle checkpoint response preventing
damaged cells from progressing through the cell cycle. FAS forms
the death-inducing signaling complex upon ligand binding, and, in
several settings, there is evidence for crosstalk between the extrinsic
and intrinsic pathways of apoptosis. Mouse double minute 2
(MDM2) homolog is a protein that in humans is encoded by the
MDM2 gene. MDM2 is an essential negative regulator of the p53
tumor suppressor. SESN1 or Sestrin 1, p53-regulated protein PA26,
is a protein encoded by the SESN1 gene. The p53 tumor suppressor
protein induces Sestrins, which play significant roles in the cellular
response to DNA damage and oxidative stress.
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studies to establish miRNAs as circulating biomarkers for
clinical use. The role of miRNAs in OS has been studied in
detail, but it is not clear whether it can be utilized to treat
patients with OS. The involvement of miRNA function in
the progression of OS has raised the possibility of the
utilization of miRNA as a novel therapy. Extensive toxicity
studies and preclinical safety trials would need to be
conducted before considering a miRNA-based therapeutic
approach. A greater understanding of the roles that different
miRNAs play in the development and progression of OS
could ultimately improve this tumor (Abarrategi et al., 2016;
Bhat et al., 2018; He et al., 2007; Jones et al., 2012; Kao et
al., 2012; Kobayashi et al., 2012; Kutmon et al., 2015;
Leichter et al., 2017; Nugent, 2014; Ram Kumar et al., 2016).
Moreover, the EIMMO, MicroInspector, miRU, MMIA,
RNA22, StarMir, and MMIA are additional tools with
variable data from biology scientists. They are web-based and
specific for identifying miRNA binding sites (Hsu et al., 2011).
There are a few additional limitations to our study. First,
the most common weakness of bioinformatics tools is the
generation of large amounts of false-positive data. We
considered the other open-source tools, such as DIANA,
TARGETSCAN, and MIRANDA, but we chose to use
miRTar because of the familiarity with this tool. Although
based on available scientific data, many of the proposed gene
interactions in these databases may be speculative. Second,
the current method of pathway analysis depends on existing
databases. Not all the miRNAs and genes linked to OS were
found in the ONCO.IO miRNA analysis tool database, which
was used to construct the pathway network. Third, the
interpretation of results based on pathway analysis tools
needs to be interpreted with caution because the miRNA field
is an evolving platform spanning from genomics to proteomics.
In conclusion, although the field of miRNA research is still
relatively new, its rapid expansion has the potential to use these
small molecules in the management of cancer. The PathVisio
analysis of Wikipathways may be a useful bioinformatic tool
for cancer research. Several miRNAs have been involved in
OS, with some demonstrated to be overexpressed while
others are downregulated. Our analysis indicates that there is
indeed potential for miRNAs to play a critical role in the
management of OS both as promising diagnostic biomarkers
and either predictive or prognostic indicators. Bioinformatics
speed has increased daily, and we expect that the PathVisio
analysis on Wikipathways may be a useful tool for cancer
research readily available for cancer research investigators
worldwide. The miRTar bioanalysis tool can be used to
determine the interaction of miRNAs with genes in the TP53
pathway, and the ONCO.IO miRNA analysis tool database
was used to identify miRNAs and OS. In OS patients
considered good responders to chemotherapy, miR-92a, miR-
99b, miR-193a-5p, and miR-422a expression increased, while
miR-132 decreased. This is the first application of PathVisio
to determine miRNA pathways in osteosarcoma to the best of
our knowledge. PathVisio is a full pathway editor with the
potentiality to illustrate the biological events, augment
graphical elements, and elucidate all the biological structures
and interactions with standard external database identifiers.
MiRNAs have the potential to become a useful diagnostic
and prognostic tool in the management of OS.
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